AksharChem India Limited has informed the Exchange about Review of ratings on the enhanced bank facilities
AKSHARCHEM · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
CARE Ratings has reaffirmed the credit ratings on AksharChem India's bank facilities totaling ₹143.41 crore, including a new ₹20 crore short-term vendor financing facility rated CARE A2+. The long-term rating stays at CARE A- and short-term at CARE A2+. However, CARE has revised the company's outlook from Stable to Negative, citing sustained weak operating performance, with 9MFY26 margins falling to 4.43% and a net loss of ₹5.24 crore versus a profit last year. The negative outlook also reflects concerns over the new PPT silica plant's delayed break-even, a 50% US tariff impact on exports, and rising debt coverage pressure (total debt/PBILDT worsened to 8.46x in 9MFY26 from 2.69x in FY25). The ratings are supported by experienced promoters, a strong export franchise, and a comfortable capital structure with overall gearing at 0.39x.
The outlook revision to Negative is a warning signal for investors — it suggests CARE could downgrade the rating if profitability and debt metrics don't improve soon. The company has a watch on its near-term performance, and shareholders may see pressure on the stock given the weak quarterly results and project execution risks, though the underlying rating remains investment-grade.